Please login to the form below

Not currently logged in
Email:
Password:

Teva fights off Novartis to market generic famciclovir tablets

Teva wins favourable ruling against Novartis for a preliminary injunction related to the Israeli firm's famciclovir treatment for genital herpes

Israeli-based Teva has received a favourable ruling from the US District Court for the District of New Jersey regarding a lawsuit filed by Swiss pharmaceutical company Novartis for a preliminary injunction related to Teva's famciclovir, a generic version of Novartis' Famvir treatment for genital herpes.

Teva's ANDA to market famciclovir tablets in 125 mg, 250 mg and 500 mg has already been granted final approval by the FDA.

Famvir had annual sales of approximately USD 200m in the US for the twelve months to 30 June 2007, based on IMS data. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity, which will begin from the date of first commercial marketing.

Teva is currently involved in patent litigation with Novartis concerning this product. A trial date has yet to be set.

7th September 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Medscape Education Global

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....

Latest intelligence

Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....
Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...